What is HC Wainwright's Forecast for UTHR FY2025 Earnings?

United Therapeutics Co. (NASDAQ:UTHR - Free Report) - Stock analysts at HC Wainwright dropped their FY2025 earnings estimates for United Therapeutics in a research note issued on Monday, May 5th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings per share of $27.31 for the year, down from their prior forecast of $27.95. HC Wainwright currently has a "Buy" rating and a $425.00 target price on the stock. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share. HC Wainwright also issued estimates for United Therapeutics' FY2026 earnings at $29.50 EPS, FY2027 earnings at $32.32 EPS, FY2028 earnings at $34.56 EPS and FY2029 earnings at $36.57 EPS.

UTHR has been the topic of a number of other reports. Morgan Stanley raised their price objective on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a report on Thursday, May 1st. JPMorgan Chase & Co. dropped their price target on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research note on Thursday, May 1st. UBS Group upped their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Bank of America raised United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price on the stock in a research report on Monday, April 21st. Finally, Wells Fargo & Company reaffirmed an "equal weight" rating and set a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $392.00.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $295.02 on Wednesday. The company has a market capitalization of $13.31 billion, a P/E ratio of 12.96, a price-to-earnings-growth ratio of 0.97 and a beta of 0.58. United Therapeutics has a 52 week low of $260.41 and a 52 week high of $417.82. The company's 50 day moving average price is $300.98 and its two-hundred day moving average price is $343.30.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. During the same quarter last year, the firm posted $6.17 earnings per share. United Therapeutics's revenue was up 17.2% compared to the same quarter last year.

Institutional Trading of United Therapeutics

Several large investors have recently bought and sold shares of the business. Cerity Partners LLC raised its holdings in United Therapeutics by 30.4% in the 4th quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $4,098,000 after buying an additional 2,702 shares during the last quarter. Milestone Asset Management LLC lifted its holdings in shares of United Therapeutics by 56.5% during the fourth quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company's stock worth $1,014,000 after purchasing an additional 1,037 shares during the period. Korea Investment CORP grew its stake in shares of United Therapeutics by 6.2% in the fourth quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock worth $13,863,000 after purchasing an additional 2,300 shares during the last quarter. Janney Montgomery Scott LLC increased its holdings in United Therapeutics by 9.1% in the fourth quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company's stock valued at $3,326,000 after purchasing an additional 789 shares during the period. Finally, Burney Co. lifted its holdings in United Therapeutics by 113.3% during the 4th quarter. Burney Co. now owns 23,922 shares of the biotechnology company's stock worth $8,441,000 after buying an additional 12,705 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the transaction, the executive vice president now owns 36,781 shares in the company, valued at approximately $11,261,606.58. This trade represents a 23.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Tommy G. Thompson sold 2,500 shares of the company's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now directly owns 8,480 shares of the company's stock, valued at $2,703,424. This represents a 22.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 75,500 shares of company stock worth $24,245,880 in the last ninety days. Insiders own 11.90% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.